Rosuvastatin Is Effective to Decrease CD8 T-Cell Activation Only in HIV-Infected Patients With High Residual T-Cell Activation Under Antiretroviral Therapy.

Details

Serval ID
serval:BIB_E22BF0297D71
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Rosuvastatin Is Effective to Decrease CD8 T-Cell Activation Only in HIV-Infected Patients With High Residual T-Cell Activation Under Antiretroviral Therapy.
Journal
Journal of Acquired Immune Deficiency Syndromes (1999)
Author(s)
Weiss L., Chevalier M.F., Assoumou L., Paul J.L., Alhenc-Gelas M., Didier C., Taibi S., Manea E.M., Campa P., Girard P.M., Costagliola D.
Working group(s)
IMEA 043-CESAR trial working group
ISSN
1944-7884 (Electronic)
ISSN-L
1525-4135
Publication state
Published
Issued date
2016
Peer-reviewed
Oui
Volume
71
Number
4
Pages
390-398
Language
english
Notes
Publication types: Clinical Trial, Phase II ; Journal Article ; Research Support, Non-U.S. Gov't Publication Status: ppublish
Abstract
OBJECTIVE: The aim of the trial was to evaluate in patients under antiretroviral therapy (ART) the effect of rosuvastatin on cellular and soluble markers of immune activation/inflammation, as well as to identify patients who better benefit from statin administration.
METHODS: IMEA-043-CESAR was a phase II open-label pilot trial that enrolled patients under suppressive ART and CD4 <500/mm. Patients received rosuvastatin (20 mg/d) for 12 weeks. The primary outcome was the variation at week 12 (W12) in the proportion of CD38HLA-DRCD8 T lymphocytes. Secondary outcomes included evolution of other markers of T-cell activation and of inflammatory biomarkers between baseline, W12, and W24.
RESULTS: Fifty patients were enrolled; end points were available for 43 patients. When considering all patients, the proportion of CD38HLA-DRCD8 T cells did not significantly decline throughout the follow-up. However, the proportion of CD38CD8T cells significantly decreased at W12 [median percentage change of -22.2% (-32.3; +1.4)]. Principal component analysis allowed identification of 3 groups of patients based on their baseline activation/inflammation profiles, 1 group with elevated levels of CD8 T-cell activation, and a small group with high levels of systemic inflammation and low levels of T-cell activation. Half of the patients exhibited relatively low levels of inflammation and activation. The proportion of activated CD8 T cells significantly decreased only in the particular group of patients with high baseline CD8 T-cell activation.
CONCLUSIONS: This study shows that combining rosuvastatin with effective ART can result in a sustained decrease in CD8 T-cell activation and highlights the importance of identifying patients who can benefit from specific immunotherapeutic strategies.
Keywords
Adult, Anti-HIV Agents/therapeutic use, Biomarkers/blood, Biomarkers/metabolism, Blood Coagulation, CD8-Positive T-Lymphocytes/drug effects, CD8-Positive T-Lymphocytes/physiology, Drug Therapy, Combination, Female, HIV Infections/drug therapy, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology, Inflammation/blood, Inflammation/metabolism, Lymphocyte Activation/drug effects, Male, Middle Aged, Pilot Projects, Rosuvastatin Calcium/pharmacology, Virus Replication
Pubmed
Web of science
Create date
05/04/2016 16:51
Last modification date
20/08/2019 16:06
Usage data